利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.044 秒)

    Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
    1.
    发明授权
    Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient 有权
    羧酸化合物和含有与活性成分相同的药物组合物

    公开(公告)号：US08138335B2

    公开(公告)日：2012-03-20

    申请号：US12551860

    申请日：2009-09-01

    申请人： Atsushi Naganawa ,  Maki Iwahashi ,  Atsushi Kinoshita ,  Atsushi Shimabukuro ,  Seiji Ogawa ,  Koji Yano ,  Kaoru Kobayashi ,  Yutaka Okada ,  Yoko Kishida ,  Shouji Kawauchi ,  Kohki Tsukamoto ,  Yoko Matsunaga ,  Fumio Nambu

    发明人： Atsushi Naganawa ,  Maki Iwahashi ,  Atsushi Kinoshita ,  Atsushi Shimabukuro ,  Seiji Ogawa ,  Koji Yano ,  Kaoru Kobayashi ,  Yutaka Okada ,  Yoko Kishida ,  Shouji Kawauchi ,  Kohki Tsukamoto ,  Yoko Matsunaga ,  Fumio Nambu

    IPC分类号： C07D265/36 ,  A61K31/535

    CPC分类号： C07D307/80 ,  A61K31/343 ,  A61K31/538 ,  C07D265/36 ,  C07D317/48

    摘要： A compound represented by formula (I) wherein the symbols in the formula are the same meanings as those in specification, salts thereof, solvates thereof, or prodrugs thereof binds to DP receptor and shows antagonistic activity for DP receptor. Thus, it is useful for prevention and/or treatment of diseases such as allergic disease (e.g., allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (e.g., atopic dermatitis and urticaria), diseases (e.g., cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (e.g., scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis, etc. Since it specifically binds to DP receptor and binds weakly to other prostaglandins receptors, they can be pharmaceuticals having little side effect.

    摘要翻译： 由式（I）表示的化合物，其中式中的符号与说明书中的符号相同，其盐，溶剂合物或其前药与DP受体结合并显示DP受体的拮抗活性。 因此，它可用于预防和/或治疗过敏性疾病（例如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），系统性肥大细胞增多症，伴有全身性肥大细胞活化的病症，过敏性休克， 支气管收缩，荨麻疹，湿疹，伴有瘙痒的疾病（例如特应性皮炎和荨麻疹），伴随瘙痒的行为的结果产生的疾病（例如白内障，视网膜脱离，炎症，感染和睡眠障碍）（例如， 搔抓和殴打），炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿关节炎，胸膜炎，溃疡性结肠炎等。由于其特异性结合DP受体并且弱结合到其他前列腺素受体，它们可以是具有 小副作用。

    CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
    2.
    发明申请
    CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT 有权
    羧酸化合物和含有相同活性成分的药物组合物

    公开(公告)号：US20100029631A1

    公开(公告)日：2010-02-04

    申请号：US12551860

    申请日：2009-09-01

    申请人： Atsushi Naganawa ,  Maki Iwahashi ,  Atsushi Kinoshita ,  Atsushi Shimabukuro ,  Seiji Ogawa ,  Koji Yano ,  Kaoru Kobayashi ,  Yutaka Okada ,  Yoko Kishida ,  Shouji Kawauchi ,  Kohki Tsukamoto ,  Yoko Matsunaga ,  Fumio Nambu

    发明人： Atsushi Naganawa ,  Maki Iwahashi ,  Atsushi Kinoshita ,  Atsushi Shimabukuro ,  Seiji Ogawa ,  Koji Yano ,  Kaoru Kobayashi ,  Yutaka Okada ,  Yoko Kishida ,  Shouji Kawauchi ,  Kohki Tsukamoto ,  Yoko Matsunaga ,  Fumio Nambu

    IPC分类号： A61K31/538 ,  C07D265/36 ,  A61P37/08 ,  A61P11/06

    CPC分类号： C07D307/80 ,  A61K31/343 ,  A61K31/538 ,  C07D265/36 ,  C07D317/48

    摘要： A compound represented by formula (I) wherein the symbols in the formula are the same meanings as those in specification, salts thereof, solvates thereof, or prodrugs thereof binds to DP receptor and shows antagonistic activity for DP receptor. Thus, it is useful for prevention and/or treatment of diseases such as allergic disease (e.g., allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (e.g., atopic dermatitis and urticaria), diseases (e.g., cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (e.g., scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis, etc. Since it specifically binds to DP receptor and binds weakly to other prostaglandins receptors, they can be pharmaceuticals having little side effect.

    摘要翻译： 由式（I）表示的化合物，其中式中的符号与说明书中的符号相同，其盐，溶剂合物或其前药与DP受体结合并显示DP受体的拮抗活性。 因此，它可用于预防和/或治疗过敏性疾病（例如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），系统性肥大细胞增多症，伴有全身性肥大细胞活化的病症，过敏性休克， 支气管收缩，荨麻疹，湿疹，伴有瘙痒的疾病（例如特应性皮炎和荨麻疹），伴随瘙痒的行为的结果产生的疾病（例如白内障，视网膜脱离，炎症，感染和睡眠障碍）（例如， 搔抓和殴打），炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿关节炎，胸膜炎，溃疡性结肠炎等。由于其特异性结合DP受体并且弱结合到其他前列腺素受体，它们可以是具有 小副作用。

    Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
    4.
    发明申请
    Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient 有权
    羧酸化合物和含有与活性成分相同的药物组合物

    公开(公告)号：US20070004716A1

    公开(公告)日：2007-01-04

    申请号：US10572578

    申请日：2004-09-16

    申请人： Atsushi Naganawa ,  Maki Iwahashi ,  Atsushi Kinoshita ,  Atsushi Shimabukuro ,  SeijiKoji Ogawa ,  Koji Yano ,  Kaoru Kobayashi ,  Yutaka Okada ,  Yoko Kishida ,  Shouji Kawauchi ,  Kohki Tsukamoto ,  Yoko Matsunaga ,  Fumio Nambu

    发明人： Atsushi Naganawa ,  Maki Iwahashi ,  Atsushi Kinoshita ,  Atsushi Shimabukuro ,  SeijiKoji Ogawa ,  Koji Yano ,  Kaoru Kobayashi ,  Yutaka Okada ,  Yoko Kishida ,  Shouji Kawauchi ,  Kohki Tsukamoto ,  Yoko Matsunaga ,  Fumio Nambu

    IPC分类号： A61K31/538 ,  C07D265/36

    CPC分类号： C07D307/80 ,  A61K31/343 ,  A61K31/538 ,  C07D265/36 ,  C07D317/48

    摘要： A compound represented by formula (I) wherein the symbols in the formula are the same meanings as those in specification, salts thereof, solvates thereof, or prodrugs thereof binds to DP receptor and shows antagonistic activity for DP receptor. Thus, it is useful for prevention and/or treatment of diseases such as allergic disease (e.g., allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (e.g., atopic dermatitis and urticaria), diseases (e.g., cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (e.g., scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis, etc. Since it specifically binds to DP receptor and binds weakly to other prostaglandins receptors, they can be pharmaceuticals having little side effect.

    摘要翻译： 由式（I）表示的化合物，其中式中的符号与说明书中的符号相同，其盐，溶剂合物或其前药与DP受体结合并显示DP受体的拮抗活性。 因此，它可用于预防和/或治疗过敏性疾病（例如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），系统性肥大细胞增多症，伴有全身性肥大细胞活化的病症，过敏性休克， 支气管收缩，荨麻疹，湿疹，伴有瘙痒的疾病（例如特应性皮炎和荨麻疹），伴随瘙痒的行为的结果产生的疾病（例如白内障，视网膜脱离，炎症，感染和睡眠障碍）（例如， 搔抓和殴打），炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿关节炎，胸膜炎，溃疡性结肠炎等。由于其特异性结合DP受体并且弱结合到其他前列腺素受体，它们可以是具有 小副作用。